Wave Life Sciences (WVE) Capital Expenditures Growth (1y) (2015 - 2026)
Wave Life Sciences (WVE) Capital Expenditures Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,933.35 Bn | 1,933.29 Bn | - | - |
| 3 | Akari Therapeutics | 1,063.56 Bn | 1,063.56 Bn | - | - |
| 4 | BeOne Medicines | 468.54 Bn | 463.75 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.20 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 63.57 Bn | 63.57 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.75 Bn | 34.74 Bn | 959.66 Mn | 143.40% |
| 10 | Wave Life Sciences | 1.19 Bn | 642.40 Mn | - | 165.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 165.45% |
| Dec 31, 2025 | -101.16% |
| Sep 30, 2025 | -35.25% |
| Jun 30, 2025 | 488.46% |
| Mar 31, 2025 | -60.43% |
| Dec 31, 2024 | -75.84% |
| Sep 30, 2024 | 93.43% |
| Jun 30, 2024 | -27.78% |
| Mar 31, 2024 | -14.72% |
| Dec 31, 2023 | 74.51% |
| Sep 30, 2023 | -56.67% |
| Jun 30, 2023 | -85.37% |
| Mar 31, 2023 | 135.10% |
| Dec 31, 2022 | 1,260.00% |
| Sep 30, 2022 | 366.33% |
| Jun 30, 2022 | 45.13% |
| Mar 31, 2022 | 92.59% |
| Dec 31, 2021 | -97.31% |
| Sep 30, 2021 | 50.77% |
| Jun 30, 2021 | 149.26% |